首页> 外文期刊>Diabetes, obesity & metabolism >Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates
【24h】

Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates

机译:每周一次施用长效的成纤维细胞生长因子21类似物在肥胖的人和非人类灵长类动物中不同地调节脂质,骨质周转标记,血压,血压和体重,血液压力和体重

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analogue, in obese people with hypertriglyceridaemia on atorvastatin, with or without type 2 diabetes.
机译:目的:评估PF-05231023的安全性,耐受性,药代动力学和药效学和药效学和药效学,一种长效的成纤维细胞生长因子21(FGF21)类似物,在阿托伐他汀对阿托伐他汀的高胰岛素血症,有或没有2型糖尿病。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号